Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

189.93 -0.47 (-0.25%)
Official Closing Price Updated: 7:00 PM EDT, Aug 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,206,540
Open 190.78
Bid (Size) 187.48 (1)
Ask (Size) 191.86 (1)
Prev. Close 190.40
Today's Range 188.10 - 191.01
52wk Range 135.85 - 193.91
Shares Outstanding N/A
Dividend Yield 3.12%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Stocks Retirees Should Absolutely Love
All of these stocks can provide steady income to retired investors. 
Via The Motley Fool
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia

Performance

YTD
+18.84%
+18.84%
1 Month
+11.78%
+11.78%
3 Month
+17.76%
+17.76%
6 Month
+9.74%
+9.74%
1 Year
+24.81%
+24.81%

More News

Read More
The Defensive Sectors And VIX Have NOT Given The All-Clear Signal
Via Talk Markets
Topics Stocks
Exposures US Equities
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Via Benzinga
A Closer Look at AbbVie's Options Market Dynamics
Via Benzinga
Warren Buffett's Approach To Investing In Election Years
Via Benzinga
Elliott Wave Technical Analysis: AbbVie Inc.
Via Talk Markets
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
Via PressReach
Exposures Product Safety
AbbVie, Leidos, KKR And More On CNBC's 'Final Trades'
Via Benzinga
Large Cap Biopharma And Healthcare, A Port In A Storm
Via Talk Markets
Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever.
Via The Motley Fool
8 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early
Via Investor's Business Daily
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Via InvestorPlace
7 Stocks Set for a Major Bull Run
Via InvestorPlace
3 Powerhouse Growth Stocks to Load Up On During This Bull Market Cycle
Via InvestorPlace
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Via Benzinga
AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
Via MarketBeat
Topics Earnings Intellectual Property
Exposures Financial Intellectual Property
Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
Via MarketBeat
3 High-Yield Dividend Stocks That Are Looking Super Hot
Via InvestorPlace
3 Dividend-Paying ETFs to Secure Your Passive Income Stream
Via InvestorPlace
Topics ETFs
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
From Alector, Inc.
Via GlobeNewswire
AbbVie Wins Analyst Confidence with Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations
Via Benzinga
Lockheed Martin To Rally Over 14%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Why AbbVie Stock Was Cruising Higher on Thursday
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.